secwatch.observer — SEC 8-K summary
======================================

Issuer:     Septerna, Inc. (SEPN)
CIK:        0001984086
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106540
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Septerna Q2 net loss $24.8M; cash $379.2M; Novo Nordisk upfront $195M extends runway into 2029
--------------------------------------------------------------------------------

- Net loss of $24.8M for Q2 2025, up from $16.4M in Q2 2024; R&D expenses $22.2M, G&A $6.9M.
- Cash, cash equivalents and marketable securities $379.2M at June 30, 2025; plus $195M upfront from Novo Nordisk received in July, extending cash runway at least into 2029.
- PTH1R agonist program: development candidate selection expected in Q3 2025, Phase 1 start in H1 2026.
- SEP-631 Phase 1 trial initiating in Q3 2025 for mast cell diseases.
- COO Liz Bhatt promoted to President effective August 1, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1984086/000095017025106540/0000950170-25-106540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1984086/000095017025106540/sepn-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer